Scarica l'app Stockscreener
10.42
0.00%
0.00
Dopo l'orario di chiusura:
10.22
-0.20
-1.92%
Precedente Chiudi:
$10.42
Aprire:
$10.84
Volume 24 ore:
635.72K
Relative Volume:
3.51
Capitalizzazione di mercato:
$194.88M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+25.09%
1M Prestazione:
+61.55%
6M Prestazione:
+305.45%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.9775
$11.88
Intervallo di 1 settimana:
$7.82
$11.88
Portata 52W:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Nome
Kalaris Therapeutics Inc
Settore
Industria
Telefono
650-249-2727
Indirizzo
400 CONNELL DRIVE, BERKELEY HEIGHTS
Confronta KLRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
10.42 | 194.88M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-07-23 | Ripresa | Piper Sandler | Neutral |
| 2025-05-07 | Iniziato | Leerink Partners | Outperform |
| 2025-04-08 | Iniziato | William Blair | Outperform |
Kalaris Therapeutics Inc Borsa (KLRS) Ultime notizie
Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement - Latham & Watkins LLP
Kalaris Therapeutics raises $50M privately - MSN
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha
Kalaris stock price target raised to $26 at Citizens on TH103 data - Investing.com Canada
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing - TipRanks
Kalaris Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Kalaris Rises On Positive Early Data From Neovascular AMD Trial And $50Mln Financing Boost - Nasdaq
Aspen Aerogels Announces Amendment to MidCap Credit Facility - The Manila Times
Vine Hill Capital Investment Corp. II Announces Pricing of Upsized $200 Million Initial Public Offering - The Manila Times
Future Mineral Announces Options Grant - The Manila Times
LACAHSA Board Approves $11.4M for Emergency Rental Assistance Funding, Bringing Total Measure A Prevention Investments to $29.5M in 2025 - The Manila Times
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - The Manila Times
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - GlobeNewswire Inc.
Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in nAMD - TradingView — Track All Markets
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD - The Manila Times
Kalaris reports positive early data for TH103 in AMD treatment By Investing.com - Investing.com UK
Kalaris Therapeutics reports positive initial Phase 1a data for TH103 - marketscreener.com
Gold hits 5 week high – More gains aheadSector-Based Investing & Free Phenomenal Trading Returns - Bollywood Helpline
Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) Biggest Owners Are Private Equity Firms Who Got Richer After Stock Soared 51% Last Week - 富途牛牛
Kalaris Therapeutics Inc. $KLRS Shares Sold by Gilead Sciences Inc. - MarketBeat
Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms - ts2.tech
Is Kalaris Therapeutics Inc. stock a good choice for value investorsEarnings Beat & Verified High Yield Trade Plans - Newser
Kalaris Therapeutics (KLRS) Stock Analysis Report | Financials & Insights - Benzinga
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $11.50 Consensus Target Price from Brokerages - Defense World
Kalaris Therapeutics Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Plan Your Future With Strategic Investing - earlytimes.in
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully - Yahoo Finance
What analysts say about Kalaris Therapeutics Inc stockCandlestick Pattern Analysis & Rapid Capital Growth - earlytimes.in
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - The Globe and Mail
Kalaris (Nasdaq: KLRS) to present at Noble Capital 21st Emerging Growth Conference - Stock Titan
Kalaris Therapeutics, Inc. (KLRS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What risks investors should watch in Kalaris Therapeutics Inc. stockJuly 2025 Short Interest & Short-Term High Return Strategies - newser.com
Equities Analysts Offer Predictions for KLRS Q4 Earnings - Defense World
Leerink Partnrs Issues Pessimistic Outlook for KLRS Earnings - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans - Sahm
What’s next for Kalaris Therapeutics Inc. stock priceTrade Exit Summary & Trade Opportunity Analysis - newser.com
Will Kalaris Therapeutics Inc. stock benefit from commodity pricesLong Setup & Daily Volume Surge Trade Alerts - newser.com
What MACD and RSI say about Kalaris Therapeutics Inc.2025 Trading Recap & Risk Controlled Stock Alerts - newser.com
Can Kalaris Therapeutics Inc. stock deliver surprise earnings beat - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsMarket Growth Summary & Stepwise Trade Execution Plans - newser.com
Kalaris stock rating reiterated at Strong Buy by Raymond James - Investing.com Canada
Kalaris Therapeutics Reports Q3 2025 Financial Progress - MSN
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsWeekly Investment Report & Verified Momentum Watchlists - newser.com
Kalaris Therapeutics Inc Azioni (KLRS) Dati Finanziari
Non sono disponibili dati finanziari per Kalaris Therapeutics Inc (KLRS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.31%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):